UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 17, 2011
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
|
| Florida
|
|
001-33357
|
|
65-0643773 |
| (State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer |
| of incorporation)
|
|
|
|
Identification No.) |
| |
|
|
|
| 2 Snunit Street |
|
|
| Science Park, POB 455 |
|
|
| Carmiel, Israel
|
|
20100 |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code +972-4-988-9488
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Explanatory Note
This amendment to the Current Report on Form 8-K originally filed by Protalix BioTherapeutics, Inc.
(the “Company”) on March 18, 2011 amends such filing to include, as an exhibit, the opinion of
Morrison & Foerster LLP, as counsel to the Company, with respect to the legality of the shares of
common stock issued pursuant to the underwriting agreement described in the original Current Report
on Form 8-K, which opinion is attached hereto and incorporated herein by reference as Exhibit 5.1.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| 5.1 |
|
Opinion of Morrison & Foerster LLP. |
2